Search Result

Results for "

tumor targeting agent

" in MedChemExpress (MCE) Product Catalog:

By Targets:	TNF Receptor (1) ADC Cytotoxin (1) Adenosine Receptor (1) Antibody-Drug Conjugates (ADCs) (1) Antifolate (1) Apoptosis (11) ATM/ATR (1) Autophagy (2) Bcl-2 Family (1) c-Kit (1) Caspase (2) CDK (1) CMV (2) CRM1 (1) Cytochrome P450 (3) DNA/RNA Synthesis (4) Drug Derivative (1) Drug Intermediate (1) Drug Isomer (1) Drug-Linker Conjugates for ADC (1) EGFR (2) Endogenous Metabolite (1) Ephrin Receptor (1) Epigenetic Reader Domain (1) FAP (1) FKBP (1) FLT3 (1) Fluorescent Dye (1) GLUT (1) GnRH Receptor (1) HDAC (3) Hexokinase (1) IGF-1R (1) Integrin (2) Interleukin Related (1) Isotope-Labeled Compounds (1) JAK (1) MDM-2/p53 (1) Microtubule/Tubulin (11) Necroptosis (1) P-glycoprotein (1) PD-1/PD-L1 (1) Peptide-Drug Conjugates (PDCs) (1) Photosensitizer (1) PSMA (1) Quinone Reductase (1) Raf (1) Ras (1) Reactive Oxygen Species (3) RET (1) ROS Kinase (1) STAT (1) Survivin (1) Thymidylate Synthase (1) Topoisomerase (4) Transmembrane Glycoprotein (1) Trk Receptor (2) VEGFR (2)
By Research Areas:	Cancer (65) Inflammation/Immunology (1) Metabolic Disease (2)

By Targets:

TNF Receptor (1)

ADC Cytotoxin (1)

Adenosine Receptor (1)

Antibody-Drug Conjugates (ADCs) (1)

Antifolate (1)

Apoptosis (11)

ATM/ATR (1)

Autophagy (2)

Bcl-2 Family (1)

c-Kit (1)

Caspase (2)

CDK (1)

CMV (2)

CRM1 (1)

Cytochrome P450 (3)

DNA/RNA Synthesis (4)

Drug Derivative (1)

Drug Intermediate (1)

Drug Isomer (1)

Drug-Linker Conjugates for ADC (1)

EGFR (2)

Endogenous Metabolite (1)

Ephrin Receptor (1)

Epigenetic Reader Domain (1)

FAP (1)

FKBP (1)

FLT3 (1)

Fluorescent Dye (1)

GLUT (1)

GnRH Receptor (1)

HDAC (3)

Hexokinase (1)

IGF-1R (1)

Integrin (2)

Interleukin Related (1)

Isotope-Labeled Compounds (1)

JAK (1)

MDM-2/p53 (1)

Microtubule/Tubulin (11)

Necroptosis (1)

P-glycoprotein (1)

PD-1/PD-L1 (1)

Peptide-Drug Conjugates (PDCs) (1)

Photosensitizer (1)

PSMA (1)

Quinone Reductase (1)

Raf (1)

Ras (1)

Reactive Oxygen Species (3)

RET (1)

ROS Kinase (1)

STAT (1)

Survivin (1)

Thymidylate Synthase (1)

Topoisomerase (4)

Transmembrane Glycoprotein (1)

Trk Receptor (2)

VEGFR (2)

By Research Areas:

Cancer (65)

Inflammation/Immunology (1)

Metabolic Disease (2)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: TNF Receptor BRK Target Protein Ligand-Linker Conjugates Ligands for Target Protein for PROTAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-149898

HA-CD44 interaction inhibitor 1	Transmembrane Glycoprotein	Cancer
Antitumor agent-109 (compound 6) is an inhibitor of hyaluronic acid (HY-B0633A) targeting to CD44, as well as an anti-tumor agent. Hyaluronic acid interacts with differentiation cluster 44 (CD44) and is involved in tumor growth and invasion. Antitumor agent-109 inhibits MDA-MB-231 cells with EC50 value of 0.59 μM .

HY-P0122

iRGD peptide 5 Publications Verification c(CRGDKGPDC)	Integrin	Cancer
iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of agents by first binding to αv-integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.

HY-163545

Tc-Me2P	Drug Derivative	Cancer
Tc-Me2P is a 99MTC-labeled acrylamide (PnAO) derivative that contains two 4-methyl-2-nitroimidazole groups. The primary activity of Tc-Me2P is as an imaging agent for tumor hypoxia. By specifically binding to hypoxic regions in tumor tissue, it can be used for single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging to detect hypoxia in tumors. Tc-Me2P can be used to study the targeting of different chemical structures in tumors and normal tissues .

HY-117841

T900607	Microtubule/Tubulin	Cancer
T900607 is an anti-tumor agent and targets microtubule polymerization .

HY-P10052

CBO-P11	VEGFR	Cancer
CBO-P11 specifically binds to receptor of VEGFR-2 and is used as targeting ligand for tumor angiogenesis. CBO-P11 is modified with a nearinfrared cyanine dye bearing an alkyne function, allowing both “click” coupling on azido-modified nanoparticles and fluorescence labelling .

HY-W520748

MJC13	FKBP	Cancer
MJC13 is an *FKBP52*-targeted agent with anti-tumor activity that can be used in prostate cancer research .

HY-128776

Antitumor agent-19	TNF Receptor	Cancer
Antitumor agent-19 is an antitumor agent that targets tumor-associated macrophages (TAMs) and can be used as a potent TAMs modulator. Antitumor agent-19 can increase TNF-alpha levels in tumor cells with EC₅₀ values???of 17.18 μM and 18.87 μM in RAW 264.7 cells and BMDM cells, respectively .

HY-168953

Lysosomal P-gp targeted agent 1	P-glycoprotein Apoptosis Bcl-2 Family Reactive Oxygen Species Caspase	Cancer
Lysosomal P-gp targeted agent 1 (Compound 14) is an anti-tumor agent targeting lysosomal P-glycoprotein (Pgp). Lysosomal P-gp targeted agent 1 is selectively transported into lysosomes by overexpressed Pgp, release nitric oxide (NO) to generate reactive oxygen species (ROS), resulting in lysosomal membrane permeabilization (LMP) and inducing apoptosis. Lysosomal P-gp targeted agent 1 can overcome P-glycoprotein-mediated drug resistance and lead to cell cycle arrest, but relatively low toxicity to normal cells. Lysosomal P-gp targeted agent 1 has antitumor activity, significantly inhibits tumor volume .

HY-124624

PBOX-15	Microtubule/Tubulin Apoptosis	Cancer
PBOX-15 is a microtubule targeting agent. PBOX-15 induces apoptosis by promoting tubulin depolymerization in tumor cells .

HY-162348

Antitumor agent-145	Necroptosis	Cancer
Antitumor agent-145 (Compound Ir5) is a tumor inhibitor with remarkable fluorescence and mitochondrial targeting, which exerts anti-cancer effects by inducing necroptosis and activating the necroptosis-related immune response .

HY-162239

Anticancer agent 187	Others	Cancer
Anticancer agent 187 (Compound 4) is an anticancer agent that can target sarcoma cells in tumor-bearing mouse models. Anticancer agent 187 exhibits cytotoxic activity against HepG2, Caco2, and MCF-7 cells .

HY-163301

Antitumor agent-139	Reactive Oxygen Species	Cancer
Antitumor agent-139 (compound 9b) is a liver - and mitochondria-targeting gold(I) complexe, and produces reactive oxygen species (ROS) and facilitates DNA excretion. Antitumor agent-139 inhibits tumor growth in a patient-derived xenograft model of hepatocellular carcinoma .

HY-149019

Antitumor agent-70	c-Kit Apoptosis	Cancer
Antitumor agent-70 (compound 8b) has anti-tumor activity and can induce cell apoptosis. Antitumor agent-70 inhibits multiple myeloma with an IC₅₀ value of 0.12 μM. Antitumor agent-70 is a potential multi-targeted kinase inhibitor especially for c-Kit .

HY-155034

Antitumor agent-102	Topoisomerase GLUT	Cancer
Antitumor agent-102 (compound 10) is a conjugate of Topoisomerase I inhibitor SN38 and glucose transporter inhibitor, targeting to colorectal cancer. Antitumor agent-102 induces higher concentrations of free SN38 in tumor tissues than Irinotecan (HY-16562) .

HY-156675A

Plecstatin-1 hydrochloride 1 Publications Verification	Microtubule/Tubulin	Cancer
Plecstatin-1 hydrochloride is an anticancer agent containing organoeuropium. Plecstatin-1 hydrochloride selectively targets plectin, a scaffolding protein and cellular connector, in tumor spheroids .

HY-159891

Microtubule destabilizing agent-2	Microtubule/Tubulin Apoptosis Caspase	Cancer
Microtubule destabilizing agent-2 (Compound 21) is an orally active and selective antitumor compound targeting microtubule protein. Microtubule destabilizing agent-2 destabilizes microtubule proteins and inhibits microtubule polymers. Microtubule destabilizing agent-2 arrests the G0/G1 phase in human tumor cells. Microtubule destabilizing agent-2 induces Apoptosis by activating the cascade pathway of caspases. Microtubule destabilizing agent-2 has anti-inflammatory activity, as inhibiting TNF-α and IL-6 in vitro. Microtubule destabilizing agent-2 reduces tumors growth in xenograft mice .

HY-170842

TDK-HCPT	Apoptosis	Cancer
TDK-HCPT is a small-molecule conjugate that links glutathione-sensitive thiamine disulfide to the chemotherapy drug 10-Hydroxycamptothecin (HY-N0095) via a thioketal bond. TDK-HCPT can target tumor cells and prolong the retention of chemotherapy agents within tumor cells. TDK-HCPT can inhibit tumor growth, induce apoptosis of tumor cells, and has anti-tumor activity .

HY-106168

Thymectacin NB1011	Thymidylate Synthase	Cancer
Thymectacin (NB1011) is an agent selectively targeting tumor cells that have a high expression of thymidylate synthase (TS). Thymectacin is an aryloxy phosphoramidate derivative of BVdU (brivudin) .

HY-W012161

Alanylphenylalanine L-Alanyl-L-phenylalanine; H-Ala-Phe-OH	Endogenous Metabolite	Cancer
Alanylphenylalanine is a potential antitumor agent that targets DNA via metal coordination. The complex of Alanylphenylalanine and Au (III) can bind to DNA and inhibit tumor cell proliferation[1][2].

HY-15855

Fosbretabulin tromethamine	Microtubule/Tubulin	Cancer
Fosbretabulin (tromethamine), also known as combretastatin A4 phosphate (CA4P), is a vascular disrupting agent evaluated for its efficacy against anaplastic thyroid carcinoma (ATC). It targets tumor neovasculature, causing acute and reversible reductions in tumor blood flow and central necrosis .

HY-16532

Zoptarelin doxorubicin AEZS-108; AN-152	Peptide-Drug Conjugates (PDCs) GnRH Receptor	Cancer
Zoptarelin doxorubicin (AEZS-108; AN-152) is a hybrid anticancer agent, containing Zoptarelin and Doxorubicin. Zoptarelin doxorubicin has been used to research targeting tumors expressing LHRH receptors. Zoptarelin doxorubicin abolishes tumor progression and induces remarkable apoptosis in vitro .

HY-N0093A

Ancitabine Cyclocytidine; Cyclo-CMP	DNA/RNA Synthesis CMV Autophagy	Cancer
Ancitabine is the precursor of the anticancer agent Cytarabine (HY-13605), which targets targets related to cell metabolism and proliferation. Ancitabine can inhibit tumor cell proliferation, interfere with the DNA synthesis process of tumor cells, and prevent cell division. Under alkaline pH conditions, Ancitabine can be quantitatively converted into Cytarabine and can be used in the study of cancers such as colorectal cancer .

HY-N0093

Ancitabine hydrochloride 1 Publications Verification Cyclocytidine hydrochloride; Cyclo-CMP hydrochloride; Cyclo-C	Autophagy CMV DNA/RNA Synthesis	Cancer
Ancitabine hydrochloride is the precursor of the anticancer agent Cytarabine (HY-13605), which targets targets related to cell metabolism and proliferation. Ancitabine hydrochloride can inhibit tumor cell proliferation, interfere with the DNA synthesis process of tumor cells, and prevent cell division. Under alkaline pH conditions, Ancitabine hydrochloride can be quantitatively converted into Cytarabine and can be used in the study of cancers such as colorectal cancer .

HY-151207

Anticancer agent 81	Apoptosis ADC Cytotoxin	Cancer
Anticancer agent 81 (Compound 37b3) is an anticancer agent and can induce tumor cell cycle arrest and apoptosis. Anticancer agent 81 can be used as a payload to conjugate with Trastuzumab (HY-P9907) to obtain the *antibody–agent* conjugate (ADC*) T-PBA. T-PBA maintained its mode of target* and internalization ability of Trastuzumab .

HY-147918

Anticancer agent 73	DNA/RNA Synthesis	Cancer
Anticancer agent 73 (compound CIB-3b) is a anticancer agent, potently targeting TAR RNA-binding protein 2 (TRBP) and disrupts its interaction with Dicer. Anticancer agent 73 can rebalance the expression profile of oncogenic or tumor-suppressive miRNAs. Anticancer agent 73 suppresses the proliferation and metastasis of HCC in vitro and in vivo .

HY-149718

Antitumor agent-123	JAK HDAC	Cancer
Antitumor agent-123 (Copmound 4d) effectively inhibits multiple kinase targets with anti-cancer effects, including JAK2, JAK3, HDAC1 and HDAC6, with IC₅₀ values of 34.6 and 2.6 μM for JAK2 and JAK3, respectively. Antitumor agent-123 exhibits moderate activity in solid tumor models .

HY-171331

AB-3PRGD2	PD-1/PD-L1 Integrin	Cancer
AB-3PRGD2 is a radiotherapeutic agent targeting integrin α_vβ₃. AB-3PRGD2 shows improved tumor uptake and prolonged tumor retention, leading to significantly enhanced tumor growth suppression. AB-3PRGD2 can remodel the tumor immune microenvironment by upregulating PD-L1 expression and increasing tumor-infiltrating CD8 ⁺ T cells .

HY-W054292

tert-Butyl-DCL (OtBu)KuE(OtBu)2	PSMA	Cancer
tert-Butyl-DCL is a small molecule PSMAM inhibitor with anticancer activity that targets prostate-specific membrane antigen (PSMA). tert-Butyl-DCL is also an effective bioimaging agent that has high selectivity and affinity, allowing it to target and highlight specific receptors on the surface of tumor cells .

HY-19916A

Lisavanbulin dihydrochloride BAL-101553 dihydrochloride	Microtubule/Tubulin	Cancer
Lisavanbulin (BAL-101553) dihydrochloride is the prodrug of the microtubule targeting agent Avanbulin (BAL 27862) (HY-106008). Lisavanbulin dihydrochloride exhibits antitumor activity, especially in tumors that express high levels of end-binding protein 1 .

HY-19916

Lisavanbulin BAL-101553	Microtubule/Tubulin	Cancer
Lisavanbulin (BAL-101553) is the prodrug of the microtubule targeting agent Avanbulin (BAL 27862) (HY-106008). Lisavanbulin exhibits antitumor activity, especially in tumors that express high levels of end-binding protein 1 .

HY-146432

Antitumor agent-60	Apoptosis Raf Ras ROS Kinase MDM-2/p53	Cancer
Antitumor agent-60 (compound 20) is a potent antitumor agent, targeting RAS-RAF signaling pathway and binding to CRAF with a K_d value of 3.93 μM. Antitumor agent-60 induces apoptosis by blocking cell cycle at G2/M phase. Antitumor agent-60 enhances the level of p53 and ROS. Antitumor agent-60 causes oval and irregular nucleus in cancer cells. Antitumor agent-60 can suppress the growth of tumor to some extent in A549 xenograft model .

HY-155485

Abi-DZ-1	Others	Cancer
Abi-DZ-1 is a potential multifunctional theranostic agent via the HIF1α/OATPs Pathway. Abi-DZ-1 can be used in the research of tumor-targeted imaging and precision therapy .

HY-147699

FRα-IN-1	Antifolate	Cancer
FRα-IN-1 (Compound 4) is a tumor-targeting agent. FRα-IN-1 shows selective anticancer activity towards folate receptors (FRα and FRβ) expression cells .

HY-13762

Tesmilifene	Cytochrome P450	Cancer
Tesmilifene is an antihistamine agent and a chemical sensitizer. Tesmilifene targets cytochrome P450, exhibits hormonal effects on DNA synthesis in MCF-7 cells, and stimulates the tumor growth in mouse/rat models. Tesmilifene overcomes multidrug resistance .

HY-13762A

Tesmilifene hydrochloride	Cytochrome P450	Cancer
Tesmilifene hydrochloride is an antihistamine agent and a chemical sensitizer. Tesmilifene hydrochloride targets cytochrome P450, exhibits hormonal effects on DNA synthesis in MCF-7 cells, and stimulates the tumor growth in mouse/rat models. Tesmilifene hydrochloride overcomes multidrug resistance .

HY-P10792

HER2-targeted peptide H6F	EGFR	Cancer
HER2-targeted peptide H6F is a HER2 targeting peptide that binds to HER2 to target breast cancer cells, with the amino acid sequence YLFFVFER. The HER2-targeted peptide H6F can be conjugated with the bifunctional chelating agent hydrazinonicotinamide (HYNIC) for radiolabeling with 99mTc. Single-photon emission computed tomography (SPECT) imaging shows that the labeled HER2-targeted peptide H6F specifically accumulates in HER2-positive MDA-MBA-453 tumor-bearing mice models. The HER2-targeted peptide H6F can be used for tumor molecular imaging studies .

HY-168717

Antitumor agent-190	Hexokinase Microtubule/Tubulin Reactive Oxygen Species	Cancer
Antitumor agent-190 (Compound 26) is a Hexokinase 2 inhibitor that demonstrates significant anti-tumor activity by targeting microtubules and Hexokinase 2, with an IC₅₀ value of 0.764 μM against MD-MBA-231 cells. Antitumor agent-190 effectively inhibits the activity of Hexokinase 2, leading to the accumulation of Reactive Oxygen Species and dysfunction of the mitochondrial membrane potential (MMP), thereby promoting apoptosis and blocking the cell cycle .

HY-144793

Deac-SS-Biotin	Microtubule/Tubulin	Cancer
Deac-SS-Biotin is a potent antitumor agent with improved tumor targeting effects and reduced off-target toxicities. Deac-SS-Biotin uptakes into the cells through biotin-mediated internalization. Deac-SS-Biotin combined with DTT (Glutathione mimetic) can effectively inhibit microtubule assembly and displays greater antitumor activity .

HY-170947

Antitumor agent-195	STAT Quinone Reductase	Cancer
Antitumor agent-195 (compound 16c) is a dual targeting agent of STAT3 and NQO1. Antitumor agent-195 significantly inhibits phosphorylation of STAT3 at Tyr705 at a concentration of 1 μM and effectively induce Apoptosis in MDAMB-231 and MDA-MB-468 breast cancer cells. Antitumor agent-195 as a NQO1 substrate strongly increases ROS generation and causes severe DNA damage in a dose-dependent manner. Antitumor agent-195 shows encouraging anti-tumor efficacy in the MDA-MB-231 xenograft model .

HY-145406

IHCH-3064	Adenosine Receptor HDAC	Inflammation/Immunology Cancer
IHCH-3064 is a dual-acting compounds targeting Adenosine A2A Receptor and HDAC. IHCH-3064 exhibits potent binding to A2AR (Ki=2.2 nM) and selective inhibition of HDAC1 (IC50=80.2 nM), with good antiproliferative activity against tumor cell lines in vitro. IHCH-3064 is a tumor immunotherapeutic agent.

HY-P9968

Nimotuzumab	EGFR	Cancer
Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a K_D of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .

HY-13622B

Elomotecan TFA BN 80927 TFA	Topoisomerase	Cancer
Elomotecan TFA is a potent inhibitor of topoisomerases I and II. Elomotecan TFA is a camptothecin analog belonging to the homocamptothecin family (hCPT). Elomotecan TFA reduces the proliferation of different tumor cells with higher potency than other anticancer agents of reference targeting topoisomerases I and II .

HY-13622A

Elomotecan BN 80927 free base	Topoisomerase	Cancer
Elomotecan (BN 80927 free base) is a potent inhibitor of topoisomerases I and II. Elomotecan is a camptothecin analog belonging to the homocamptothecin family (hCPT). Elomotecan reduces the proliferation of different tumor cells with higher potency than other anticancer agents of reference targeting topoisomerases I and II .

HY-157850

BP-M345	Microtubule/Tubulin	Cancer
BP-M345 (compound 5) is a potent, cancer cell-targeting antiproliferative agent that exhibits low toxicity to non-tumor cells. BP-M345 inhibits cancer cell proliferation with a GI₅₀ value ranging from 0.17 to 0.45 μM .

HY-13622

Elomotecan hydrochloride BN 80927	Topoisomerase	Cancer
Elomotecan hydrochloride (BN 80927) is a potent inhibitor of topoisomerases I and II. Elomotecan hydrochloride (BN 80927) is a camptothecin analog belonging to the homocamptothecin family (hCPT). Elomotecan hydrochloride (BN 80927) reduces the proliferation of different tumor cells with higher potency than other anticancer agents of reference targeting topoisomerases I and II .

HY-170779

DOTA-NI-FAPI-04	FAP	Cancer
DOTA-NI-FAPI-04 is a FAP inhibitor (IC₅₀ = 7.44 nM). By integrating FAP targeting with hypoxia-sensitive groups (nitroimidazole), DOTA-NI-FAPI-04 significantly enhances tumor uptake and retention capabilities. DOTA-NI-FAPI-04 chelates metallic isotopes (such as ⁶⁸Ga and ¹⁷⁷Lu) through DOTA to produce radioactive probes ([ ⁶⁸Ga]Ga/DOTA-NI-FAPI-04 and [ ¹⁷⁷Lu]Lu/DOTA-NI-FAPI-04), which can be used for research in tumor diagnostics and therapeutic agents. DOTA-NI-FAPI-04 holds dual targeting potential in the fields of cancer imaging, tumor microenvironment analysis, and radionuclide therapy, particularly suitable for scenarios where the tumor stroma and hypoxic regions synergistically interact .

HY-13762S

Tesmilifene-d4	Isotope-Labeled Compounds Cytochrome P450	Cancer
Tesmilifene-d4 is the deuterium labeled Tesmilifene (HY-13762). Tesmilifene is an antihistamine agent and a chemical sensitizer. Tesmilifene targets cytochrome P450, exhibits hormonal effects on DNA synthesis in MCF-7 cells, and stimulates the tumor growth in mouse/rat models. Tesmilifene overcomes multidrug resistance .

HY-P99233

Camidanlumab HuMax-TAC	Interleukin Related	Cancer
Camidanlumab (HuMax-TAC) is a CD25 monoclonal antibody. Camidanlumab targets the cell-surface antigen CD25, which is over-expressed on a variety of hematological tumors and shows limited expression on normal tissues. Camidanlumab can be used for synthesis of antibody agent conjugates (ADCs) to research several diseases including lymphoma and leukemia .

HY-173211

anti-TNBC agent-8	Photosensitizer	Cancer
anti-TNBC agent-8 (Compound TP2) is a photodynamic therapeutic agent targeting mitochondrial DNA G4 (mtG4). Under white light irradiation, its IC₅₀ against 4T1 cells is 0.42 μM. anti-TNBC agent-8 binds tightly to mtG4 and generates a large amount of reactive oxygen species (ROS) under white light irradiation, leading to the loss of mitochondrial membrane potential (MMP), a decrease in ATP production, and an increase in the ROS level. This, in turn, induces significant apoptosis in triple-negative breast cancer (TNBC) cells, exerting the activity of inhibiting tumor cell growth. anti-TNBC agent-8 can be used in the research of triple-negative breast cancer.

HY-16350

BOLD-100 NKP-1339; IT-139; KP-1339	DNA/RNA Synthesis Apoptosis	Cancer
BOLD-100 (NKP-1339; IT-139) is the first-in-class ruthenium-based anticancer agent in development against solid cancer with limited side effects. BOLD-100 induces G2/M cell cycle arrest, blockage of DNA synthesis, and induction of apoptosis via the mitochondrial pathway. BOLD-100 has a high tumor targeting potential, strongly binds to serum proteins such as albumin and transferrin and activates in the reductive tumor milieu .

Cat. No.	Product Name

HY-L112

Chemotherapy Drug Library

154 compounds

Chemotherapy is one of the most common treatments for cancer. It can be used alone for some types of cancer or in combination with other treatments such as radiation or surgery. Chemotherapy drugs usually target cells at different phases of the cell cycle and inhibit tumor proliferation and avoid cancer cell invasion and metastasis. It is a cancer treatment method that kills cancer cells with drugs.

Chemotherapeutic agents can be classified into alkylating agents, antimetabolites, antimicrotubular agents, antibiotics, etc. according to the mechanism of action. MCE offers a unique collection of 154 chemotherapy drugs, which is a useful tool for cancer treatment research.

HY-L173

Anti-Ovarian Cancer Compound Library

2,315 compounds

Ovarian cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate and poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors and sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread and drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer.

MCE designs a unique collection of 2,315 compounds with definite or potential anti-ovarian cancer activity, which mainly targeting the main targets of ovarian cancer such as PARP, ATM/ATR, VEGFR and HIF/HIF Prolyl-Hydroxylase, etc. It is an essential tool for development and research of anti-ovarian compounds.

HY-L213

Anti-Cancer Approved Drug Library

283 compounds

The anti-cancer drug library meticulously collects all drugs approved by FDA and other major national drug regulatory authorities for cancer treatment. These drugs cover a variety of cancer types, including but not limited to lung cancer, breast cancer, colorectal cancer, leukemia, and other common cancers. The library includes a wide range of drugs, from classic chemotherapeutic agents to cutting-edge targeted therapies and immunotherapies. It contains various types of drug compounds with different mechanisms of action. There are cytotoxic drugs that directly kill cancer cells, as well as drugs that work by modulating the tumor microenvironment, inhibiting tumor angiogenesis, and activating the immune system. This diversity provides researchers with a broad range of perspectives and options for intervention strategies.

This library can be used for basic research on cancer treatment, exploring new targets and new mechanisms of drug action; Conducting drug reuse research to look for potential therapeutic effects of existing drugs on other cancer types or diseases; Or conducting research into combination drugs to optimize cancer treatment.

MCE has collected 283 small-molecule compounds with cancer indications, which are good tools for drug repurposing.

HY-L064

Glutamine Metabolism Compound Library

1,197 compounds

Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH.

Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment.

MCE owns a unique collection of 1,197 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.

Cat. No.	Product Name	Type

HY-D1716

S0456	Fluorescent Dyes/Probes
S0456 is a raw material that plays a crucial role in the construction of the folate receptor-targeted near-infrared dye OTL 38 (HY-139579). S0456 is connected to the modified folic acid to form OTL 38, endowing OTL 38 with good optical properties, high affinity, and specificity. S0456 can be used in the research of tumor optical imaging agents .

Cat. No.	Product Name	Type